摘要
背景:Idarucizumab是一种作为特定的达比加群解毒剂的人源化单克隆抗体片段,被批准用于逆转达比加群相关的可能的关键部位出血或出血持续,尽管局部手术后止血。此外,它也可以用于在紧急手术或其他高风险出血的侵入性程序中逆转达比加群酯抗凝血活性。 目的:在本研究中,我们根据现有的文献资料,通过PubMed,EMBASE和Cochrane图书馆的广泛研究,使用idarucizumab,达比加群及其组合作为Mesh术语,重点研究高影响力的研究,讨论idarucizumab。 结果:一些研究已经证明了idarucizumab能够逆转达比加群酯相关性凝血病的实验室测量,然而其在现实世界患者中的效力和安全性仍然不是很清楚,因为现有数据的稀缺性应当通过广泛的上市后监视。 结论:将idarucizumab作为达比加群解毒剂在临床上的应用是临床医生的有用工具。迅速恢复达比加群抗凝活性的可能性使其使用更简单,更易于管理。
关键词: 伊达珠单抗,达比加群,解毒剂,抗凝活性,止血,抗凝药物。
图形摘要
Current Drug Targets
Title:Idarucizumab: What Should We Know?
Volume: 19 Issue: 1
关键词: 伊达珠单抗,达比加群,解毒剂,抗凝活性,止血,抗凝药物。
摘要: Background: Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis. Moreover, it can also be applied to reverse the dabigatran anticoagulant activity in emergency surgery or in other invasive procedure at high risk of bleeding.
Objective: In this study, we discuss idarucizumab in light of the available literature data by conducting extensive research in the PubMed, EMBASE and Cochrane Library on the topic, using idarucizumab, dabigatran and their combinations as Mesh terms, and focusing on high impact investigations.
Results: Several studies have demonstrated the capacity of idarucizumab to reverse laboratory measures of dabigatran-associated coagulopathy, however its efficacy and safety in real world patients are still not very clear because of the scarcity of available data which should be assessed with an extensive post market surveillance.
Conclusion: The introduction of idarucizumab as dabigatran antidote in clinical practice represents a useful tool for clinicians. The possibility to rapidly restore the anticoagulation activity of dabigatran makes its use simpler and more manageable.
Export Options
About this article
Cite this article as:
Idarucizumab: What Should We Know?, Current Drug Targets 2018; 19 (1) . https://dx.doi.org/10.2174/1389450118666170925155943
DOI https://dx.doi.org/10.2174/1389450118666170925155943 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adult Neurogenesis in Epileptogenesis: An Update for Preclinical Finding and Potential Clinical Translation
Current Neuropharmacology A Medical Approach to the Monoamine Oxidase Inhibition by Using 7Hbenzo[ e]perimidin-7-one Derivatives
Current Topics in Medicinal Chemistry Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology High Sensitivity C-Reactive Protein as a Potential Biomarker of Neuroinflammation in Major Psychiatric Disorders
Current Psychiatry Reviews Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Pharmacological Properties of Glutamatergic Drugs Targeting NMDA Receptors and their Application in Major Depression
Current Pharmaceutical Design Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry Prevalence of Cognitive Impairment and Dementia in Malays – Epidemiology of Dementia in Singapore Study
Current Alzheimer Research Depressed Serum 25-Hydroxyvitamin D Levels Increase Hospital Stay and Alter Glucose Homeostasis in First-ever Ischemic Stroke
Current Neurovascular Research Recent Advances in Small Molecule Antagonists of the Corticotropin- Releasing Factor Type-1 Receptor-Focus on Pharmacology and Pharmacokinetics
Current Medicinal Chemistry Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Validation of Texas Christian University Psychosocial Functioning and Motivation Scales in Iranian Persons Who Use Drugs
Current Drug Research Reviews Serine Proteases in Bone Disease
Current Rheumatology Reviews Recent Advances in Industrial Application of Tannases: A Review
Recent Patents on Biotechnology Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects
Current Medicinal Chemistry Metabolic Changes in Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry